Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
79
Recruiting, any sponsor type, condition "dry eye"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed622
79 trials
Showing 1 to 25, recently updated first.
AbbVieAbbVie (ABBV)
NCT06977724 · 36 participants (planned) · Start Aug 26, 2025 · Primary completion Mar 2029
Drug: ABBV-319 · For: Dry Eye Syndrome; Systemic Lupus Erythematosus
Sites: Margate, Florida; Tampa, Florida; Orland Park, Illinois · 9 sites in all
Astellas Institute for Regenerative MedicineAstellas (ALPMY)
NCT03178149 · 42 participants (planned) · Start Jan 30, 2019 · Primary completion Dec 31, 2027
Drug: ASP7317; tacrolimus and 3 more · For: Age-Related Macular Degeneration
Sites: Phoenix, Arizona; Los Angeles, California; Palo Alto, California · 20 sites in all
Samsung Medical CenterAcademic, hospital or other
NCT07397949 · 60 participants (planned) · Start May 11, 2026 · Primary completion Dec 2026
Drug: Rebamipide 2% ophthalmic solution; Diquafosol 3% ophthalmic solution · For: Dry Eye Disease (DED); Cataract
Sites: Seoul, South Korea
National Cancer Institute (NCI)NIH
NCT03816345 · 300 participants (planned) · Start Jul 16, 2019 · Primary completion Mar 30, 2028
Drug: Cabozantinib; Fluoropyrimidine and 4 more · For: Autoimmune Disease; Crohn Disease; Dermatomyositis and 11 more
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 52 sites in all
Pleryon Therapeutics (Hangzhou) LimitedIndustry
NCT07593404 · 40 participants (planned) · Start May 28, 2026 · Primary completion Nov 2026
Drug: Part 2 ABR2 At least twice a day for 28 days; Part 1: ABR2 single dose in one eye · For: Dry Eye Syndrome (DES)
Sites: Waterloo, Canada
National Eye Institute (NEI)NIH
NCT04339764 · 20 participants (planned) · Start Sep 23, 2020 · Primary completion May 31, 2029
Drug: iPSC-derived RPE/PLGA transplantation · For: Dry Age-Related Macular Degeneration; Geographic Atrophy
Sites: Baltimore, Maryland; Bethesda, Maryland
Bausch & Lomb IncorporatedIndustry
NCT07778888 · 20 participants (planned) · Start Oct 19, 2026 · Primary completion Feb 2027
Drug: BL1107 · For: Dry Eye Disease
Sites: Newport Beach, California
- Two Arm, Double-blind, Phase III Study Assessing Efficacy and Safety of Ianalumab Versus Placebo, in Participants With Sjögren's Disease With High Symptom BurdenPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07621809 · 570 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 15, 2029
Drug: VAY736; Placebo · For: Sjögren´s Disease
Sites: Peoria, Arizona; Searcy, Arkansas; Van Nuys, California · 72 sites in all
- 3% Diquafosol Ophthalmic Solution for Active Moderate-to-Severe Vernal KeratoconjunctivitisPivotal-lookingRecruiting
The University of Hong KongAcademic, hospital or other
NCT06903884 · 94 participants (planned) · Start Feb 9, 2026 · Primary completion Jun 30, 2028
Drug: 3% Diquafosol ophthalmic solution and 0.1% Cyclosporin A cationic ophthalmic emulsion; 0.1% Cyclosporin A cationic ophthalmic emulsion · For: Vernal Keratoconjunctivitis
Sites: Hong Kong, Hong Kong
Scott & Christie and Associates, PCAcademic, hospital or other
NCT07926594 · 100 participants (planned) · Start Oct 27, 2026 · Primary completion Jun 30, 2027
Drug: Acoltremon 0.003% (TRYPTYR) · For: Dry Eye Disease
Sites: Scottsdale, Arizona; Cranberry Township, Pennsylvania
- A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's DiseasePivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07737743 · 344 participants (planned) · Start Aug 24, 2026 · Primary completion Feb 19, 2029
Drug: DDY391; Placebo · For: Sjögren's Disease
Sites: Avondale, Arizona; Clearwater, Florida; Tampa, Florida · 31 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07649265 · 63 participants (planned) · Start Sep 24, 2026 · Primary completion Nov 20, 2028
Drug: HBM7020 · For: Rheumatoid Arthritis; Systemic Lupus Erythematosus; Systemic Sclerosis and 1 more
Sites: Brisbane, Australia
National Institute of Dental and Craniofacial Research (NIDCR)NIH
NCT07281456 · 60 participants (planned) · Start Dec 18, 2025 · Primary completion Dec 15, 2030
Drug: Tofacitinib · For: Sjogren's Syndrome
Sites: Bethesda, Maryland
Ocular Aesthetics, LLC dba Ocular Clinical TrialsAcademic, hospital or other
NCT07904728 · 50 participants (planned) · Start Aug 25, 2026 · Primary completion Mar 15, 2027
Drug: Cyclosporine 0.1% Ophthalmic Solution · For: Dry Eye Disease (DED); Contact Lens Discomfort (CLD)
Sites: Houston, Texas
Lubris Bio Pty LtdIndustry
NCT07118241 · 80 participants (planned) · Start Sep 17, 2025 · Primary completion Dec 30, 2026
Drug: Recombinant Human Proteoglycan 4; Vehicle Control · For: Sjögren's Syndrome
Sites: Sydney, Australia; Brisbane, Australia; Maroochydore, Australia · 7 sites in all
Antengene Biologics LimitedIndustry
NCT07732309 · 149 participants (planned) · Start Sep 26, 2026 · Primary completion Dec 1, 2028
Drug: ATG-201 · For: Systemic Lupus Erythematosus; Systemic Sclerosis (SSc); Sjogren's Disease and 1 more
Sites: Bengbu, China; Hefei, China; Beijing, China · 22 sites in all
Lubris Bio Pty LtdIndustry
NCT07118254 · 15 participants (planned) · Start Sep 17, 2025 · Primary completion Mar 2027
Drug: rhPRG4 450ug/ml; Vehicle Control · For: Ocular Graft Versus Host Disease
Sites: Sydney, Australia; Brisbane, Australia; Melbourne, Australia
- An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye DiseasePivotal-lookingRecruiting
Dompé Farmaceutici S.p.AIndustry
NCT07503886 · 417 participants (planned) · Start May 12, 2026 · Primary completion Dec 27, 2026
Drug: DFL24498 · For: Dry Eye Disease (DED)
Sites: Chandler, Arizona; Azusa, California; Glendale, California · 24 sites in all
Candid TherapeuticsIndustry
NCT07712939 · 105 participants (planned) · Start Jul 22, 2026 · Primary completion Mar 31, 2028
Drug: CND319 · For: Healthy Participants Study; Rheumatoid Arthritis; Sjogren's Syndrome
Sites: Melbourne, Australia
- Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseasePivotal-lookingRecruiting
Vor BiopharmaIndustry
NCT07404865 · 250 participants (planned) · Start Feb 26, 2026 · Primary completion Dec 2028
Drug: Telitacicept; Placebo · For: Primary Sjogren's Disease
Sites: Chandler, Arizona; Flagstaff, Arizona; Glendale, Arizona · 49 sites in all
TherornaIndustry
NCT07413341 · 12 participants (planned) · Start Jan 22, 2026 · Primary completion May 1, 2027
Drug: TI-0032-III injection · For: Systemic Lupus Erythematosus (SLE); Sjogren's Syndrome (SS); Systemic Sclerosis (SSc) and 2 more
Sites: Shanghai, China
- Phase III Study of OT202 in Treating Moderate to Severe Dry EyePivotal-lookingRecruiting
Ocumension Therapeutics (Suzhou) Co., LtdIndustry
NCT07740564 · 842 participants (planned) · Start Aug 25, 2026 · Primary completion Jan 2029
Drug: OT202 conc 1%; Placebo · For: Dry Eye
Sites: Bengbu, China; Hefei, China; Beijing, China · 49 sites in all
- A Study to Evaluate the Performance and Safety of Artelac® Complete MDO® Versus VISMED® MULTI Eye Drops in the Management of Moderate to Severe Dry Eye DiseasePivotal-lookingRecruiting
Dr. Gerhard Mann chem.-pharm. Fabrik GmbHIndustry
NCT07593885 · 160 participants (planned) · Start Apr 30, 2026 · Primary completion Nov 2026
Drug: Artelac® Complete MDO® Eye Drops; VISMED® MULTI Eye Drops · For: Dry Eye
Sites: Freiburg im Breisgau, Germany; Heidelberg, Germany; Tübingen, Germany · 12 sites in all
Peking University People's HospitalAcademic, hospital or other
NCT07843381 · 60 participants (planned) · Start May 1, 2026 · Primary completion Sep 16, 2027
Drug: Telitacicept 160mg; Conventional treatment · For: Sjögren's Disease; Interstitial Lung Disease
Sites: Beijing, China
- Evaluation of LacrifillRecruiting
Eye Research Associates, LLCAcademic, hospital or other
NCT07796178 · 40 participants (planned) · Start Sep 2, 2026 · Primary completion Dec 31, 2026
Drug: Lacrifill; Saline · For: Dry Eye; Ocular Surface Disease; Cataract Surgery and 1 more
Sites: Pittsburg, Kansas; Kansas City, Missouri
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.